Literature DB >> 16856885

Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.

Hiroaki Ohnishi, Koji Kandabashi, Yoshiharu Maeda, Machiko Kawamura, Takashi Watanabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16856885     DOI： 10.1111/j.1365-2141.2006.06221.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Mediastinal Mass with Hyper-eosinophilia in a Young Boy -A Diagnostic Dilemma.

Authors:  Abdul Shahid Poovathum Parambil; Shruti Prem; Priya Mary Jacob; Rekha Appukuttan Nair
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 3.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 4.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

5.  F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.

Authors:  S P Gorantla; K Zirlik; A Reiter; C Yu; A L Illert; N Von Bubnoff; J Duyster
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

6.  A case of coexisting Warthin tumor and langerhans cell histiocytosis associated with necrosis, eosinophilic abscesses and a granulomatous reaction in intraparotid lymph nodes.

Authors:  Char Loo Tan; Gangaraju Changal Raju; Fredrik Petersson
Journal:  Rare Tumors       Date:  2011-04-04

7.  Chronic eosinophilic leukemia with FIP1L1-PDGFRA transcripts after occupational and therapeutic exposure to radiation.

Authors:  Gueorgui Balatzenko; Nikolay Stoyanov; Elena Bekrieva; Margarita Guenova
Journal:  Hematol Rep       Date:  2011-10-11

8.  Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Jose A Cancelas
Journal:  Transl Oncogenomics       Date:  2006-12-05

9.  Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

Authors:  Violaine Havelange; Jean-Baptiste Demoulin
Journal:  J Blood Med       Date:  2013-08-09

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.